GRCEHealthcare · BiotechnologyGRCE Stock Forecast: Grace Therapeutics, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Grace Therapeutics, Inc. hold a median 12-month price target of $5.94 — +210.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 21 Oct 2026 — in the lower half.
GRCE stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Grace Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (20): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GRCE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GRCE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +210.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Apr 2026 | TD Cowen | Maintains | Buy | $12 → $8.00 |
| 18 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
GRCE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
- The AI build-out, every Wednesday: how AI stocks did, part by part.
GRCE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Grace Therapeutics, Inc. returned −38.0% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GRCE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Grace Therapeutics, Inc. (GRCE) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.1×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- −2.7×
Cheaper than 90% of US stocks
Cheaper than 79% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −36.2%
- Return on assets
- −10.8%
- Dividend yield
- 0.0%
Higher than 25% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Grace Therapeutics, Inc. (GRCE) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Grace Therapeutics, Inc. has a market value of $41.4M and an enterprise value of $27.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.2M.
Free cash flow in the twelve months to 30 June 2026: −$10.3M.
Trailing P/E: −4.1×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Grace Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
GRCE vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Grace Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GRCE stock
What is the GRCE stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Grace Therapeutics, Inc. have a median 12-month price target of $5.94, with estimates ranging from $3.95 to $7.93. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GRCE stock a buy right now?
Of the 2 analysts covering Grace Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Grace Therapeutics, Inc. 47 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GRCE?
As at 21 Oct 2026, Grace Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
Will GRCE stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +210.2% from the last close, and Ticker Nerd's factor model ranks Grace Therapeutics, Inc. 47 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GRCE stock forecast for 2030?
No analyst covering Grace Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRCE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.95 to $7.93 over the next 12 months.
How has GRCE stock performed over the past year?
Grace Therapeutics, Inc. returned -38.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Grace Therapeutics, Inc. currently centers on drug candidates designed to address serious neurological and pain-related conditions, including GTx-104 for aneurysmal subarachnoid hemorrhage, GTx-102 for Ataxia-Telangiectasia, and GTx-101 for postherpetic neuralgia. The company works with proprietary drug-delivery technologies aimed at improving how established molecules are formulated and administered in clinical settings. Its portfolio is positioned at the intersection of specialty pharmaceuticals and rare-disease treatment, supporting hospitals, physicians, and patients managing complex unmet medical needs. Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey.
CEO Mr. Prashant Kohli · 5 employees · United States · https://www.gracetx.com